Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC datopotamab deruxtecan advanced or metastatic non-squamous
non-small cell lung cancer (NSCLC)
Pending
TBC elafibranor Primary biliary cholangitis (PBC) Pending
TBC trofinetide Rett syndrome (RTT) Pending
TBC cipaglucosidase alfa and miglustat Pompe disease Pending
TBC zolbetuximab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
TBC momelotinib Myelofibrosis Active
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Suspended
TBC donanemab Alzheimer's disease Active
TBC omaveloxolone Friedreich’s ataxia Active
TBC Efanesoctocog alfa congenital factor VIII deficiency Active